Full Title
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-401) Administered to Patients with Acute Myeloid Leukemia (AML) following Hematopoietic Stem Cell TransplantationPurpose
The purpose of this study is to determine the best dose of an investigational treatment called MT-401 to be given after a donated (allogeneic) stem cell transplant in patients with acute myeloid leukemia (AML). MT-401 is made from T cells (a type of white blood cell) collected from the donor who provided the stem cells for the bone marrow transplant. These cells are sent to a laboratory and changed to enable them to bind to and kill cancer cells. MT-401 is given intravenously (by vein).
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have AML and be planning to have an allogeneic stem cell transplant or have cancer that persists after already having a stem cell transplant.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Boglarka Gyurkocza at 646-608-3768.
Protocol
21-059
Phase
II
Disease Status
Relapsed or Refractory